SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 12.25 GBX -2.97% Market Closed
Market Cap: 31.7m GBX

SkinBioTherapeutics PLC
Short-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SkinBioTherapeutics PLC
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
SkinBioTherapeutics PLC
LSE:SBTX
Short-Term Debt
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Short-Term Debt
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Short-Term Debt
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford BioMedica PLC
LSE:OXB
Short-Term Debt
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SkinBioTherapeutics PLC
Glance View

Market Cap
31.7m GBX
Industry
Biotechnology

SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Macclesfield, Cheshire and currently employs 7 full-time employees. The company went IPO on 2017-04-05. The firm is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis, medical device applications and others. The Company’s platform technology, SkinBiotix, is designed to promote skin health by harnessing the beneficial properties of probiotic bacteria and the active components derived from them. SkinBiotix protects the skin from infection and increases the rate of skin healing in response to injury. The firm's AxisBiotix technology is based on the emerging area of science that is focused on the gut-skin axis and the constitution of the gut microbiome plays a role in various diseases, such as psoriasis. AxisBiotix-Ps is the product developed by the Company that uses the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

SBTX Intrinsic Value
22.76 GBX
Undervaluation 46%
Intrinsic Value
Price

See Also

What is SkinBioTherapeutics PLC's Short-Term Debt?
Short-Term Debt
0 GBP

Based on the financial report for Dec 31, 2024, SkinBioTherapeutics PLC's Short-Term Debt amounts to 0 GBP.

Back to Top